Should I buy or sell BioCryst Pharmaceuticals stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BCRX shares. View BCRX analyst ratings or view top-rated stocks .

What is BioCryst Pharmaceuticals' stock price target for 2024?

7 brokers have issued 1 year price objectives for BioCryst Pharmaceuticals' shares. Their BCRX share price targets range from $10.00 to $30.00. On average, they predict the company's share price to reach $13.29 in the next twelve months. This suggests a possible upside of 195.2% from the stock's current price. View analysts price targets for BCRX or view top-rated stocks among Wall Street analysts .

How have BCRX shares performed in 2024?

BioCryst Pharmaceuticals' stock was trading at $5.99 at the beginning of 2024. Since then, BCRX shares have decreased by 24.9% and is now trading at $4.50. View the best growth stocks for 2024 here .

Are investors shorting BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 32,250,000 shares, an increase of 5.6% from the March 15th total of 30,550,000 shares. Based on an average trading volume of 3,290,000 shares, the short-interest ratio is currently 9.8 days. View BioCryst Pharmaceuticals' Short Interest .

When is BioCryst Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our BCRX earnings forecast .

How were BioCryst Pharmaceuticals' earnings last quarter?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) issued its quarterly earnings results on Monday, February, 26th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $0.04. The biotechnology company earned $93.40 million during the quarter, compared to the consensus estimate of $89.19 million.

What ETFs hold BioCryst Pharmaceuticals' stock?

ETFs with the largest weight of BioCryst Pharmaceuticals (NASDAQ:BCRX) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA) , Amplify Treatments, Testing and Advancements ETF (GERM) and Virtus LifeSci Biotech Products ETF (BBP) . LeaderShares Activist Leaders ETF (ACTV) .

What is Jon P. Stonehouse's approval rating as BioCryst Pharmaceuticals' CEO?

9 employees have rated BioCryst Pharmaceuticals Chief Executive Officer Jon P. Stonehouse on Glassdoor.com . Jon P. Stonehouse has an approval rating of 40% among the company's employees. This puts Jon P. Stonehouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 64.0% of employees surveyed would recommend working at BioCryst Pharmaceuticals to a friend.

What other stocks do shareholders of BioCryst Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioCryst Pharmaceuticals investors own include Inovio Pharmaceuticals (INO) , El Pollo Loco (LOCO) , Advanced Micro Devices (AMD) , Idera Pharmaceuticals (IDRA) , OPKO Health (OPK) , Dynavax Technologies (DVAX) , La Jolla Pharmaceutical (LJPC) , Novavax (NVAX) , Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV) .

Who are BioCryst Pharmaceuticals' major shareholders?

BioCryst Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.04%). Insiders that own company stock include Alane P Barnes , Anthony Doyle , George B Abercrombie, George B Abercrombie , Helen M Thackray, Jon P Stonehouse , Machelle Sanders, Michael L Jones, Nancy J Hutson , Vincent Milano , William P Sheridan and Yarlagadda S Babu . View institutional ownership trends .

How do I buy shares of BioCryst Pharmaceuticals?

Shares of BCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BCRX

BioCryst Pharmaceuticals (BCRX) Stock Price, News & Analysis

→ Did You Get Your Free Bitcoin Yet? (From Crypto Swap Profits) (Ad)

Free BCRX Stock Alerts

$4.50

-0.08 (-1.75%)

(As of 04/18/2024 ET)

Compare

Today's Range: $4.49
▼
$4.71
50-Day Range: $4.50
▼
$5.95
52-Week Range: $4.45
▼
$9.06

Volume: 2.96 million shs
Average Volume: 3.28 million shs
Market Capitalization: $927.68 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $13.29

Get BioCryst Pharmaceuticals alerts:

BioCryst Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 195.2% Upside
$13.29 Price Target
Short Interest: Bearish
15.64% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.85
Upright™ Environmental Score
News Sentiment: 0.70
Based on 12 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.68) to ($0.25) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.63 out of 5 stars

Medical Sector

239th out of 918 stocks

Biological Products, Except Diagnostic Industry

32nd out of 147 stocks

3.5

Analyst's Opinion

Consensus Rating
BioCryst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
BioCryst Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
15.64% of the outstanding shares of BioCryst Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
BioCryst Pharmaceuticals has a short interest ratio ("days to cover") of 9.8.
Change versus previous month
Short interest in BioCryst Pharmaceuticals has recently increased by 5.56%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
BioCryst Pharmaceuticals does not currently pay a dividend.
Dividend Growth
BioCryst Pharmaceuticals does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
BioCryst Pharmaceuticals has received a 60.25% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Influenza medication", "Clinical research services for physical health", and "Hereditary angioedema medicine" products. See details.
Environmental Sustainability
The Environmental Impact score for BioCryst Pharmaceuticals is -1.85.

2.6

News and Social Media Coverage

News Sentiment
BioCryst Pharmaceuticals has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for BioCryst Pharmaceuticals this week, compared to 3 articles on an average week.
Search Interest
Only 5 people have searched for BCRX on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
MarketBeat Follows
Only 6 people have added BioCryst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BioCryst Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.40% of the stock of BioCryst Pharmaceuticals is held by insiders.
Percentage Held by Institutions
85.88% of the stock of BioCryst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for BioCryst Pharmaceuticals are expected to grow in the coming year, from ($0.68) to ($0.25) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of BioCryst Pharmaceuticals is -3.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BioCryst Pharmaceuticals is -3.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

About BioCryst Pharmaceuticals Stock (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

BCRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BCRX Stock News Headlines

April 17, 2024 | morningstar.com

BioCryst Pharmaceuticals Inc BCRX

April 17, 2024 | finanznachrichten.de

BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 17, 2024 | markets.businessinsider.com

BioCryst: Brazilian Health Regulatory Agency Approves ORLADEYO - Quick Facts

April 17, 2024 | americanbankingnews.com

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Short Interest Up 5.6% in March

April 17, 2024 | finance.yahoo.com

BioCryst Pharmaceuticals, Inc. (BCRX)

April 17, 2024 | finance.yahoo.com

BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency

April 16, 2024 | money.usnews.com

Biocryst Pharmaceuticals Inc.

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 14, 2024 | americanbankingnews.com

BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Down 6.3%

April 11, 2024 | americanbankingnews.com

BioCryst Pharmaceuticals (NASDAQ:BCRX) Receives "Buy" Rating from Needham & Company LLC

April 3, 2024 | globenewswire.com

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 25, 2024 | globenewswire.com

BioCryst to Present at Upcoming Investor Conferences

March 18, 2024 | finance.yahoo.com

BCRX Apr 2024 6.000 put

March 17, 2024 | finance.yahoo.com

BCRX Apr 2024 6.000 call

March 17, 2024 | ca.finance.yahoo.com

BCRX Apr 2024 9.000 call

March 17, 2024 | ca.finance.yahoo.com

BCRX Apr 2024 7.000 put

March 16, 2024 | finance.yahoo.com

BCRX Apr 2024 7.000 call

March 16, 2024 | finance.yahoo.com

BCRX Apr 2024 5.000 put

March 5, 2024 | globenewswire.com

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 1, 2024 | investorplace.com

Hidden Penny Gems: 7 Stocks With Triple-Digit Growth Prospects

February 28, 2024 | seekingalpha.com

BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2023 Earnings Call Transcript

February 28, 2024 | finance.yahoo.com

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2023 Earnings Call Transcript

February 28, 2024 | markets.businessinsider.com

Analysts’ Top Healthcare Picks: BioCryst (BCRX), Veracyte (VCYT)

February 27, 2024 | seekingalpha.com

BioCryst's Revenue Gains Offset By Rising Expenses: A Closer Look

February 27, 2024 | finance.yahoo.com

Q4 2023 BioCryst Pharmaceuticals Inc Earnings Call

February 27, 2024 | finance.yahoo.com

BioCryst Pharmaceuticals Full Year 2023 Earnings: EPS Misses Expectations

See More Headlines

Receive BCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioCryst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/26/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Current Symbol: NASDAQ:BCRX
CUSIP: 09058V10
CIK: 882796
Web: www.biocryst.com
Phone: (919) 859-1302
Fax: 919-859-1314
Employees: 536
Year Founded: 1986

Price Target and Rating

Average Stock Price Target: $13.29
High Stock Price Target: $30.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +195.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.18)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-226,540,000.00
Net Margins: -68.36%
Pretax Margin: -68.26%
Return on Equity: N/A
Return on Assets: -36.96%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.31
Quick Ratio: 3.12

Sales & Book Value

Annual Sales: $331.41 million
Price / Sales: 2.80
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($2.22) per share
Price / Book: -2.03

Miscellaneous

Outstanding Shares: 206,150,000
Free Float: 197,079,000
Market Cap: $927.68 million
Optionable: Optionable
Beta: 1.90

Social Links

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Jon P. Stonehouse (Age 63)
CEO, President & Executive Director
Comp: $1.15M
Mr. Anthony J. Doyle (Age 43)
Senior VP, CFO & Treasurer
Comp: $726.42k
Ms. Alane P. Barnes (Age 58)
Senior VP, Chief Legal Officer & Corporate Secretary
Comp: $655.33k
Dr. William P. Sheridan MBBS (Age 69)
Chief Development Officer
Comp: $784.09k
Dr. Yarlagadda S. Babu (Age 71)
Chief Discovery Officer
Comp: $691.45k
Dr. Helen M. Thackray FAAP (Age 56)
M.D., Chief Research & Development Officer
Comp: $844k
Mr. Charles K. Gayer (Age 53)
Senior VP & Chief Commercial Officer
Comp: $643.43k
Mr. Michael L. Jones (Age 54)
Executive Director of Finance & Principal Accounting Officer
Mr. John D. Bluth (Age 51)
Chief Communications Officer
Ms. Stephanie Angelini
Chief People Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BCRX Stock Analysis - Frequently Asked Questions

Should I buy or sell BioCryst Pharmaceuticals stock right now?: 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BCRX shares.
View BCRX analyst ratings or view top-rated stocks.
What is BioCryst Pharmaceuticals' stock price target for 2024?: 7 brokers have issued 1 year price objectives for BioCryst Pharmaceuticals' shares. Their BCRX share price targets range from $10.00 to $30.00. On average, they predict the company's share price to reach $13.29 in the next twelve months. This suggests a possible upside of 195.2% from the stock's current price.
View analysts price targets for BCRX or view top-rated stocks among Wall Street analysts.
How have BCRX shares performed in 2024?: BioCryst Pharmaceuticals' stock was trading at $5.99 at the beginning of 2024. Since then, BCRX shares have decreased by 24.9% and is now trading at $4.50.
View the best growth stocks for 2024 here.
Are investors shorting BioCryst Pharmaceuticals?: BioCryst Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 32,250,000 shares, an increase of 5.6% from the March 15th total of 30,550,000 shares. Based on an average trading volume of 3,290,000 shares, the short-interest ratio is currently 9.8 days.
View BioCryst Pharmaceuticals' Short Interest.
When is BioCryst Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our BCRX earnings forecast.
How were BioCryst Pharmaceuticals' earnings last quarter?: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) issued its quarterly earnings results on Monday, February, 26th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $0.04. The biotechnology company earned $93.40 million during the quarter, compared to the consensus estimate of $89.19 million.

What ETFs hold BioCryst Pharmaceuticals' stock?: ETFs with the largest weight of BioCryst Pharmaceuticals (NASDAQ:BCRX) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), Amplify Treatments, Testing and Advancements ETF (GERM) and Virtus LifeSci Biotech Products ETF (BBP).LeaderShares Activist Leaders ETF (ACTV).
What is Jon P. Stonehouse's approval rating as BioCryst Pharmaceuticals' CEO?: 9 employees have rated BioCryst Pharmaceuticals Chief Executive Officer Jon P. Stonehouse on Glassdoor.com. Jon P. Stonehouse has an approval rating of 40% among the company's employees. This puts Jon P. Stonehouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 64.0% of employees surveyed would recommend working at BioCryst Pharmaceuticals to a friend.
What other stocks do shareholders of BioCryst Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BioCryst Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), El Pollo Loco (LOCO), Advanced Micro Devices (AMD), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Dynavax Technologies (DVAX), La Jolla Pharmaceutical (LJPC), Novavax (NVAX), Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV).
Who are BioCryst Pharmaceuticals' major shareholders?: BioCryst Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.04%). Insiders that own company stock include Alane P Barnes, Anthony Doyle, George B Abercrombie, George B Abercrombie, Helen M Thackray, Jon P Stonehouse, Machelle Sanders, Michael L Jones, Nancy J Hutson, Vincent Milano, William P Sheridan and Yarlagadda S Babu.
View institutional ownership trends.
How do I buy shares of BioCryst Pharmaceuticals?: Shares of BCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BCRX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial